That's according to a new technical market research report, "DNA Vaccines: Technologies and Global Markets," from BCC Research.
Among the report's findings are the following:
• "The vaccines market, once a backwater of the pharmaceutical industry, is now considered to be an attractive growth opportunity. DNA vaccines make up an emerging vaccine platform within this changing paradign. They target a wide range of traditional pharmaceutical markets, such as cancers and allergies, as well as infectious diseases."
• "New biotechnologies and nanotechnologies are driving DNA vaccine development. Particularly important to DNA vaccines reaching their potential are emerging delivery technologies such as electroporation, innovative vaccine formats such as DNA prime-adenovector boost, and novel molecular adjuvant technologies. These technologies are providing the means for achieving higher efficacy in humans that is required for commercialization of DNA vaccines."
• "These vaccines have already made significant progress to date. There are three approved DNA vaccines for animal health applications and nearly 100 clinical trials underway in humans for a wide range of diseases. There is a deep pipeline of preclinical projects."
The report is available as an electronic PDF for $4,850 at the company's Web site, by calling 866.285.7215, or be e-mail at [email protected].
Among the report's findings are the following:
• "The vaccines market, once a backwater of the pharmaceutical industry, is now considered to be an attractive growth opportunity. DNA vaccines make up an emerging vaccine platform within this changing paradign. They target a wide range of traditional pharmaceutical markets, such as cancers and allergies, as well as infectious diseases."
• "New biotechnologies and nanotechnologies are driving DNA vaccine development. Particularly important to DNA vaccines reaching their potential are emerging delivery technologies such as electroporation, innovative vaccine formats such as DNA prime-adenovector boost, and novel molecular adjuvant technologies. These technologies are providing the means for achieving higher efficacy in humans that is required for commercialization of DNA vaccines."
• "These vaccines have already made significant progress to date. There are three approved DNA vaccines for animal health applications and nearly 100 clinical trials underway in humans for a wide range of diseases. There is a deep pipeline of preclinical projects."
The report is available as an electronic PDF for $4,850 at the company's Web site, by calling 866.285.7215, or be e-mail at [email protected].
